Sulforaphane Regulates Glucose and Lipid Metabolisms in Obese Mice by Restraining JNK and Activating Insulin and FGF21 Signal Pathways

Oct 28, 2021Journal of agricultural and food chemistry

Sulforaphane controls sugar and fat metabolism in obese mice by lowering stress signals and boosting insulin and FGF21 pathways

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Daily treatment with 10 mg/kg body weight of sulforaphane significantly reduced complications of obesity in mice over 8 weeks.

Sulforaphane may alleviate nonalcoholic fatty liver disease (NAFLD) and inflammation associated with obesity.
Treatment is linked to reduced oxidative stress and adipose tissue enlargement.
Insulin resistance may be improved through the regulation of glucose and lipid metabolism.
Sulforaphane is associated with deactivating a specific protein that inhibits insulin signaling.
It may also help in overcoming resistance to a hormone involved in glucose metabolism.

AI simplified

The most common complications of obesity are metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), hyperglycemia, and low-grade inflammation. Sulforaphane (SFN) is a hydrolysate of glucosinolate (GLS) that is found in large quantities in cruciferous vegetables. The objective of this research was to evaluate the mechanism by which SFN relieves obesity complications in obese mice. C57BL/6J mice were fed a high-fat diet to induce obesity and treated daily with 10 mg/(kg body weight (bw)) SFN for 8 weeks, while a positive control group was treated daily with 300 mg/(kg bw) metformin. Our results indicated that SFN attenuated NAFLD, inflammation, oxidative stress, adipose tissue hypertrophy, and insulin resistance, as well as regulated glucose and lipid metabolism. SFN regulated glucose and lipid metabolism by deactivating c-Jun N-terminal kinase (JNK) and blocking the inhibitory effect of the insulin signaling pathway. SFN also regulated glucose metabolism by alleviating fibroblast growth factor 21 (FGF21) resistance. Our research provides an empirical basis for clinical treatment with SFN in obesity.

Full Text

Full text is available at the source.

View full text ↗

Sulforaphane Regulates Glucose and Lipid Metabolisms in Obese Mice by Restraining JNK and Activating Insulin and FGF21 Signal Pathways

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief